Home

üç nadir Çiğ overall mutation load vs incidence of p53 mutations diyalekt taahhüt türetme

TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection - ScienceDirect
TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection - ScienceDirect

Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines | PNAS
Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines | PNAS

Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells | Breast Cancer Research | Full Text
Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells | Breast Cancer Research | Full Text

Frontiers | Mutation-Derived Neoantigens for Cancer Immunotherapy
Frontiers | Mutation-Derived Neoantigens for Cancer Immunotherapy

Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients | Scientific Reports
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients | Scientific Reports

Frontiers | Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
Frontiers | Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies

Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function | PNAS
Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function | PNAS

Cancers | Free Full-Text | TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes | HTML
Cancers | Free Full-Text | TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes | HTML

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others | Nature Reviews Clinical Oncology
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others | Nature Reviews Clinical Oncology

The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases | Leukemia
The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases | Leukemia

TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection - eBioMedicine
TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection - eBioMedicine

Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes | Oncogene
Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes | Oncogene

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma - Journal of Thoracic Oncology
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma - Journal of Thoracic Oncology

Mutant p53 Drives Cancer Metastasis via RCP-Mediated Hsp90α Secretion - ScienceDirect
Mutant p53 Drives Cancer Metastasis via RCP-Mediated Hsp90α Secretion - ScienceDirect

Five‐year overall survival rate in patients with oncomorphic and... | Download Scientific Diagram
Five‐year overall survival rate in patients with oncomorphic and... | Download Scientific Diagram

High prevalence of TP53 loss and whole-genome doubling in early-onset colorectal cancer | Experimental & Molecular Medicine
High prevalence of TP53 loss and whole-genome doubling in early-onset colorectal cancer | Experimental & Molecular Medicine

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma - eBioMedicine
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma - eBioMedicine

Frontiers | Prevalence of the Brazilian TP53 Founder c.1010G>A (p.Arg337His) in Lung Adenocarcinoma: Is Genotyping Warranted in All Brazilian Patients?
Frontiers | Prevalence of the Brazilian TP53 Founder c.1010G>A (p.Arg337His) in Lung Adenocarcinoma: Is Genotyping Warranted in All Brazilian Patients?

The cancer-associated, gain-of-function TP53 variant P152Lp53 activates multiple signaling pathways implicated in tumorigenesis - Journal of Biological Chemistry
The cancer-associated, gain-of-function TP53 variant P152Lp53 activates multiple signaling pathways implicated in tumorigenesis - Journal of Biological Chemistry

Disarming mutant p53 oncogenic function - ScienceDirect
Disarming mutant p53 oncogenic function - ScienceDirect

High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort | Leukemia
High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort | Leukemia

IJMS | Free Full-Text | Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors | HTML
IJMS | Free Full-Text | Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors | HTML

The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density | npj Breast Cancer
The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density | npj Breast Cancer

Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia | Haematologica
Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia | Haematologica